State and National Contexts in Evaluating Cannabis Laws: A Case Study of Washington State

Christopher Cambron¹,3, Katarina Guttmannova ²,3, Charles B. Fleming²,4

¹ Social Development Research Group, School of Social Work, University of Washington, 9725 3rd Ave NE, Suite 401, Seattle, WA 98115
² Center for the Study of Health and Risk Behavior, Department of Psychiatry and Behavioral Sciences, University of Washington
³ Center for Studies in Demography & Ecology, University of Washington
⁴ Family & Child Nursing, University of Washington

Please send correspondence concerning this article to Christopher Cambron, Social Development Research Group, University of Washington, 9725 3rd Ave NE, Suite 401, Seattle, WA 98115. E-mail: ccambron@uw.edu

Manuscript preparation was supported by the National Institute on Drug Abuse of the National Institutes of Health under award #R21DA037341 to Dr. Guttmannova. Partial support for this research also came from the University of Washington Alcohol and Drug Abuse Institute small grant mechanism to Dr. Guttmannova and a Eunice Kennedy Shriver National Institute of Child Health and Human Development research infrastructure grant, #R24HD042828, and training grant #T32HD007543 to the Center for Studies in Demography & Ecology at the University of Washington.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Alcohol and Drug Abuse Institute. The authors have no conflict of interest to declare.

Abstract

As of January 2016, twenty three U.S. states and the District of Columbia have legalized medical or non-medical cannabis, with more likely to follow. This dynamic policy context represents a substantial challenge for policy evaluation. Part I of this paper provides a summary of state-level cannabis policy components across states and federal action regarding state-level policies. Part II presents a detailed history of cannabis policies in Washington State from 1998 to 2015 and analyzes the potential impacts of the policy changes on cannabis supply and demand. As an early adopter of both medical and non-medical cannabis policies, Washington State provides an excellent example of the key elements to be considered in evaluating the relationship between policy changes and cannabis use. We highlight the importance of the interplay of federal enforcement priorities and previously adopted state-level cannabis regimes in interpreting the potential impacts of new cannabis policies.

Keywords: cannabis policy, drug policy, policy evaluation
**Introduction**

State-level cannabis policies in the United States have become increasingly less restrictive during the past 20 years and these policies vary substantially within and across states. New policies may lead to increased cannabis consumption which, in turn, may result in societal costs from cannabis use disorders, drugged driving, physical or mental health problems, poorer educational outcomes, and reductions in workplace productivity (see Darnell, 2015 for a logic model of societal costs related to consumption; see Volkow, Baler, Compton, & Weiss, 2014 for a review of the relationship of cannabis use to health). As cannabis laws continue to evolve, evaluations of these policies will have to evolve with them. To date, evaluations of the impact of cannabis laws on cannabis use have yielded mixed or inconclusive results (see Hunt & Miles, 2015; Sznitman & Zolotov, 2015 for recent reviews).

In response to these mixed findings, multiple scholars have outlined challenges for both within- and cross-state evaluations of cannabis laws (Anderson & Rees, 2014b; Harper & Strumpf, 2012; Pacula, Powell, Heaton, & Sevigny, 2015; Pacula & Sevigny, 2014; Wall et al., 2012). Challenges include lack of adequate state-level data, possible differential impact of policy changes across age cohorts or among population subgroups, and complexities with timing and variation of cannabis policy components. Furthermore, evaluations of cannabis policies have often treated the passage of new cannabis legislation as equivalent across states regardless of the year of passage. Presenting the passage of a law as a single point in time at which cannabis shifts from illegal to legal does not take into account the shifting national context in which a state-level law passes and the potential impact of state-level variation in cannabis policy prior to passage of new laws. It is also assumed that the passage of a law has the power to immediately alter cannabis supply or demand. As we demonstrate with a case study of Washington, reality is more complicated.

Part I of this paper identifies important considerations for future cannabis policy evaluations. Part II illuminates these considerations through a detailed case study of Washington’s cannabis policy history. Washington’s history with medical and non-medical cannabis policy development and implementation provides rich examples for the study of cannabis policies. We examine a range of academic, media, advocacy, and government sources to discuss how policy change may impact cannabis supply and demand, to identify the content and implementation timelines of new policies, and to highlight the importance of federal actions. Figure 1 provides an overview of cannabis policy changes in Washington and overlays major events in other states and at the national level. We conclude with recommendations for future cannabis policy evaluations.
Figure 1. Cannabis policy timeline for Washington, successful major legislation in other states and national signals. Unsuccessful bills or ballot provisions are not shown (Ballotpedia, 2015; Barcott, 2015; Marijuana Policy Project, 2013; ProCon.org, 2015).
Part I
State-level Cannabis Policies

Current federal law prohibits growing, producing, distributing, or possessing cannabis. Many states have chosen to depart from federal prohibitions and have liberalized state-level cannabis policies. Liberalized policies can be classified into three broad categories: decriminalization, legalization of medical cannabis, and legalization of non-medical cannabis (often referred to as recreational). Decriminalization policies maintain cannabis as illegal but typically defer first-time offenders from jail and may only invoke small fines similar to traffic ticket (Kilmer, 2002; Marijuana Policy Project, 2015). Medical cannabis policies allow authorized patients to possess and use cannabis for medical purposes but vary in terms of what conditions may be treated with cannabis and how cannabis can be obtained. Medical cannabis policies may provide one or more legal supply points including dispensaries that function like pharmacies, cooperatives or collective gardens whereby patients pool resources to produce their own cannabis, or home cultivation. States may or may not require patients to register with local public health authorities and vary on the role caregivers may adopt with respect to cannabis patients. Current non-medical cannabis policies allow for the sale of cannabis to over 21 but may limit possession amounts and home cultivation.

Table 1 presents a summary of state-level cannabis policies and key policy components as of January 2016. The contents of Table 1 were derived from academic sources and web-based materials (Bestrashniy & Winters, 2015; Fairman, 2015; Marijuana Policy Project, 2013b, 2015; NORML, 2015; ProCon.org, 2015). Recent reviews have provided an in-depth consideration of heterogeneity in state-level cannabis policies (Pacula & Sevigny, 2014), compared the restrictiveness of medical cannabis policies across states (Chapman, Spetz, Lin, Chan, & Schmidt, 2016), and examined variation in medical cannabis policy components including dispensaries (Freisthler, Kepple, Sims, & Martin, 2013), patient registration (Fairman, 2015), and allowable medical conditions (Bestrashniy & Winters, 2015). Table 1 highlights the heterogeneity of policy components and timelines across states and points to not only the official enactment dates attached to policies, but also implementation realities of new policy. Of particular note is the lag between passing a medical cannabis policy and establishing dispensaries as a legal supply point. As indicated by number of patients per 1000 residents, there is also heterogeneity in program uptake by state. Although concerns have been raised that medical cannabis may spillover from patients to non-patients (Anderson & Rees, 2014a), spillover is likely limited in states with small medical cannabis programs. We emphasize that early medical cannabis policies in states such as Washington, California, and Oregon were designed and implemented to ensure patient rights to grow and possess cannabis, but did not provide clear provisions for cannabis supply. This silence on supply “made the lines between legal medical markets and illegal (or black) recreational markets blurry” (Hunt & Miles, 2015, p. 5). States without clearly defined regulations for medical cannabis supply have fostered grey markets for cannabis whereby individuals without documented medical conditions are able to easily obtain medical cannabis authorizations (Kleiman et al., 2015). This scenario has created substantial challenges for law enforcement in multiple states (Hunt & Miles, 2015).
<table>
<thead>
<tr>
<th>State</th>
<th>Decriminalization</th>
<th>Medical Legislation (ML)</th>
<th>Non-Medical Legislation (NML)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Year Passed</td>
<td>Date First ML Passed</td>
<td>ML Effective Date</td>
</tr>
<tr>
<td>Maryland</td>
<td>2014</td>
<td>4 / 2014</td>
<td>6 / 2014</td>
</tr>
<tr>
<td>New Hampshire</td>
<td>7 / 2013</td>
<td>7 / 2013</td>
<td>pending</td>
</tr>
<tr>
<td>New Jersey</td>
<td>1 / 2010</td>
<td>7 / 2010</td>
<td>8 / 2012</td>
</tr>
<tr>
<td>New York</td>
<td>1977</td>
<td>7 / 2014</td>
<td>7 / 2014</td>
</tr>
</tbody>
</table>

Notes: ML = Medical Legislation; NML = Non-Medical Legislation; NA = not applicable; oz = ounce; 1 = does not allow for smokeable marijuana; 2 = indicates possession limit for usable cannabis; 3 = home cultivation with restrictions; 4 = home cultivation not allowed for NML; 5 = medical dispensaries began selling non-medical cannabis in 10/2015.
Supply and Demand Framework and Prior Cannabis Policy Evaluations

Research on cannabis and other drug use has often invoked the supply and demand framework of economics (Birckmayer, Holder, Yacoubian, & Friend, 2004; National Research Council, 2010). Within this framework, supply and demand are interdependent sets of variables that jointly influence levels of consumption. Cannabis policy changes can potentially affect both the supply and demand side of the equation (Anderson & Rees, 2014a). Changes in cannabis demand are often examined through social norms regarding cannabis use such as favorable attitudes towards use, perceived risk of harm from cannabis use, and perception of parent, peer, or community disapproval of cannabis use. Social norms research has consistently found that measures of cannabis norms are strong proximal predictors of cannabis use (Johnston, O'Malley, Bachman, & Schulenberg, 2011a, 2011b; Kilmer, 2002). Social, economic, and cultural factors that influence cannabis demand have historically been shown to be more relevant for explaining variation in cannabis use than changes in supply (Pacula et al., 2000; Reuband, 1998). Less research has tied changes in supply factors to variation in cannabis use, perhaps because estimating changes in supply has been challenging, particularly for cannabis supplied through illegal markets (Bjarnason, Steriu, & Kokkevi, 2010). The impact of changes in legal cannabis supply on cannabis use, however, is an important question that can be empirically tested if reliable supply side indicators such as the number of dispensaries or retail stores are available (Pacula, Kilmer, Grossman, & Chaloupka, 2010). It has been hypothesized that creating a legal cannabis supply mechanism may reduce the legal costs of use by lowering the threat of arrest or severity of penalty for possession and use (specifically for those using cannabis illegally such as adolescents) and drive down monetary prices for cannabis (Anderson & Rees, 2014a; Ghosh et al., 2015). As legal cannabis markets take shape in multiple states, changes in cannabis prices resulting from supply or demand factors will be an important and complicated variable for future cannabis policy evaluators to consider (Anderson & Rees, 2014a; Caulkins et al., 2015; Pacula & Lundberg, 2014).

Research that has examined the effects of liberalization of cannabis laws on cannabis consumption has shown mixed results, with only some studies modeling the supply and demand mechanisms through which policy changes may influence cannabis use. Comprehensive evaluations of non-medical cannabis policies are yet to emerge but newly established legal cannabis markets will offer the potential to investigate how consumption reacts to changes in both supply and demand. Early evaluations of decriminalization policies enacted in the 1970s generally found little impact of policy change on cannabis use (Johnston, 1981; Single, 1989). Analyses of data from the 1990s found increased cannabis use after decriminalization after accounting for variation in police enforcement across states (Pacula, Chriqui, & King, 2003). Miech and colleagues (2015) recently noted increased cannabis use among 12th graders in California compared to all other states after a 2010 decriminalization law was passed. This study considered demand mechanisms by modeling changes in perceived risk of harm for cannabis use and disapproval for cannabis use, both of which showed decreases in California after decriminalization.

---

1 Others have sought to understand substance use in changing contexts using normalization theories (Hammersley, Jenkins, & Reid, 2001; Hathaway, Comeau, & Erickson, 2011). We restrict our consideration in this paper to economic frameworks but recognize the importance of normalization theories for substance use.
The majority of studies assessing the impact of medical cannabis policies across states have found little evidence of increases in cannabis use for either adolescents or adults (Anderson, Hansen, & Rees, 2015; Choo et al., 2014; Gorman & Charles Huber Jr, 2007; Harper, Strumpf, & Kaufman, 2012; Hasin et al., 2015; Keyes et al., 2016; Khatapoush & Hallfors, 2004; Lynne-Landsman, Livingston, & Wagenaar, 2012).\(^2\) Three studies have noted elevated cannabis consumption in states allowing for medical cannabis compared to states without (Cerdá, Wall, Keyes, Galea, & Hasin, 2012; Stolzenberg, D’Alessio, & Dariano, 2016; Wall et al., 2011). However, consideration of these results in light of state-level controls has suggested that observed differences across states are not the direct result of policy changes (Wall et al., 2016). It has been hypothesized that loosening social norms may follow liberalization of cannabis policies and serve as a precursor to changes in cannabis consumption (Hall & Weier, 2015). Indeed, some studies have explicitly modeled cannabis norms in the context of changing cannabis policies (Khatapoush & Hallfors, 2004; Stolzenberg et al., 2016; Wall et al., 2011). Epidemiological surveillance of norms has noted decreases in perceived risk of harm and disapproval for cannabis among adolescents at the national level over the past decade (Keyes et al., 2016; Schmidt, Jacobs, & Spetz, 2016). Schmidt et al. (2016) reported that states with medical cannabis laws do show more permissive norms than states without, but similar to previous studies, these differences were not attributable to medical cannabis policies. Within-state analyses from California have shown that medical cannabis advertising is linked to increased cannabis use among adolescents, suggesting that the media debates regarding new cannabis policies may impact adolescent perceptions and behavior (D’Amico, Miles, & Tucker, 2015). Similarly, exposure to anti-cannabis media messaging has been connected to lower cannabis use and stricter cannabis norms (Block, Morwitz, Putsis Jr, & Sen, 2002; Czyzewska & Ginsburg, 2007; Terry-McElrath, Emery, Szczypka, & Johnston, 2011).

In focusing on variation in medical cannabis policies, Pacula et al. (2015) pointed to supply mechanisms through which policy can impact consumption. Pacula and colleagues reported that states with legal authorization of cannabis dispensaries showed increased cannabis use and frequency of cannabis-related treatment admissions. Wen, Hockenberry, and Cummings (2014), employing a similar strategy, did not find use patterns related to any specific policy component, including whether states allowed for supply of cannabis through state sanctioned dispensaries. Wen and colleagues, however, did find evidence of increased cannabis use for adults over 21 and a higher probability of cannabis initiation among 12 to 20 years olds in medical cannabis states. Both Pacula et al. (2015) and Wen et al. (2014) addressed differences in medical cannabis programs across states by specifically modeling cannabis policy components. More research, however, is needed to understand the extent of potential spillover of medical cannabis from dispensaries to non-patients given reports that higher density of dispensaries has been related to elevated cannabis consumption among adults (Freisthler & Gruenewald, 2014) and the presence of medical cannabis dispensaries near schools has been linked to cannabis use among young children (Shi, 2016). Future policy evaluations that hope to capture the effects of changes in supply must recognize that grey market

---

\(^2\) Two studies have actually noted significant decreases in cannabis consumption among adolescents in states with medical cannabis laws (Choo et al., 2014; Keyes et al., 2016).
dispensaries have existed in states such as Washington, Oregon, Michigan, and Montana despite the absence of legal sanctioning under state policies (Anderson & Rees, 2014b) (See Table 1).

**Federal Enforcement and Priorities**

State-level policies are embedded within the context of federal laws. If growers, producers and distributors are deterred from entering the market by the threat of federal intervention, then we would expect a smaller shift in the legal state-level cannabis supply after medical cannabis policies are enacted (Stanley, 2014). The legal mechanisms by which federal authorities may prosecute those involved in state-sanctioned cannabis markets are yet to be fully tested in the courts and will not be discussed in detail here (see Garvey & Yeh, 2014 for a discussion of federal preemption of state law). The Supreme Court has ruled that federal authority may supersede state-level medical cannabis law under the Controlled Substances Act (CSA). In 2005, *Gonzalez v. Raich* held that federal authorities may, under the Commerce Clause, prohibit growing cannabis for personal use by authorized patients within states allowing medical cannabis (Rosenbaum, 2005). The court has also ruled that a medical necessity defense may not supersede federal authority given the schedule I classification of cannabis (Stanley, 2014). Thus, state-level cannabis laws currently offer no protection from federal enforcement for growers, producers, distributors, or users.

Federal enforcement priorities have not been clear or consistent across administrations. The Clinton administration adopted the position that the CSA did not preempt California’s medical cannabis laws and offered no Constitutional challenge (Rosenbaum, 2005). The administration, however, opposed cannabis as a medicine and reaffirmed that doctors prescribing a Schedule I substance were subject to license revocation under the CSA (National Drug Strategy Network, 1997). The second Bush administration broadly contended that medical cannabis was a criminal violation of the CSA regardless of state law (Rosenbaum, 2005). Following *Gonzalez v. Raich*, the Drug Enforcement Agency (DEA) increased the volume of raids on cannabis growers, producers, and distributors across the country (Sekhon, 2009). Over 200 raids on medical cannabis dispensaries were reported in California during President Bush’s time in office (Mikos, 2011). Departing from the position that federal drug enforcement involves prohibition alone, the Obama administration and the Department of Justice (DOJ) under Attorney General Eric Holder vocalized support for states experimenting with medical cannabis policies and, in 2009, issued the Ogden memo (ProCon.org, 2012). This memo provided clear guidance to U.S. Attorneys responsible for federal prosecution under the CSA in the thirteen states that had enacted medical cannabis legislation at that time. U.S. Attorneys were directed not to prosecute individuals or businesses operating in compliance with state cannabis laws (Ogden, 2009). Media reports and cannabis scholars have recognized the Ogden memo as a catalyst for expansion of cannabis supply in states with poorly defined regulations by emboldening current and prospective cannabis growers, producers, and distributors (Anderson & Rees, 2014b; Breathes, 2012; Brush, 2013; Fairman, 2015; Kleiman, 2015; Marijuana Policy Project, 2013a; Sekhon, 2009).

However, precise measurement of supply expansion within states after the Ogden memo is challenging given lack of dispensary tracking data and their grey market status in multiple states. Colorado, which currently allows dispensaries and began tracking them in 2010, noted a 25% expansion in the number of dispensaries in Denver
from 2010 to 2013 (Schuermeyer et al., 2014). Research tracking medical cannabis patient registrations over time noted substantially larger increases in medical cannabis patient registrations in Colorado, Michigan, and Montana from 2009 to 2010 compared to other medical cannabis states, suggesting state-specific increases in demand (Fairman, 2015). These three states, along with Washington, have been identified as states where grey market dispensaries arose prior to 2009 (Marijuana Policy Project, 2013b). This expansion of cannabis dispensaries in Colorado, Michigan, Montana, and Washington after the Ogden memo is colloquially referred to as the green rush (Anderson & Rees, 2014b). Empirical studies of cannabis consumption and norms in the general population suggest that 2009 may represent an important turning point for demand. In Colorado, perceptions of risk of harm decreased among young adults in the year following the Ogden memo (Schuermeyer et al., 2014). Explicitly testing the impact of the Ogden memo in Colorado, Wang, Roosevelt and Heard (2013) reviewed emergency room records and found a significant increase in cannabis ingestion among children under age 12, suggesting spillover of cannabis to minors. National surveillance data suggests an accelerated drop in perceived risk of harm for cannabis among adolescents after 2009 (Schmidt et al., 2016) and a reversal of previously observed downward trends in cannabis use among high school students in 2009 (Johnson et al., 2015). National opinion trends report that the percentage of the population in favor of cannabis legalization rose 11% points from 2010 to 2013 and has since leveled (Motel, 2015). The extent to which the Ogden memo influenced the growth of state-sanctioned cannabis supply, grey market cannabis supply, demand for cannabis, or cannabis norms is yet to be comprehensively investigated.³

In June 2011 and August 2013, the DOJ issued two further memos to U.S. Attorneys providing more guidance for federal action regarding state-level cannabis laws. Referred to as the Cole memos, the first Cole memo was interpreted by many as direction for U.S. Attorneys to interrogate medical cannabis providers who continued to operate in legal grey areas (Barcott, 2015). Possibly in response to the first Cole memo, medical cannabis patient registrations declined from 2011 to 2013 in Colorado, Montana, and Michigan (Fairman, 2015). However, President Obama stated in November 2012 on national television that cannabis use in states that have passed legalization measures was not a priority for the DOJ (Garvey & Yeh, 2014). A second Cole memo was issued in 2013, after Washington and Colorado had voted to legalize non-medical cannabis, and more closely reflected President Obama’s public statements. This memo clarified federal priorities in states liberalizing cannabis policies and tasked U.S. Attorneys with preventing the following: cannabis sales to minors, illegal cartel activity, interstate trafficking of cannabis, drugged driving, any detriments to public health, and violence or accidents involved with the cannabis trade (Southall & Healy, 2013). The memo also contended that states with established and effective regulatory structures should manage growers, distributors, or sellers regardless of the size of operation and, therefore, do not warrant federal intervention (Cole, 2013). The common interpretation of the memo signaled a

³ A working paper currently in progress by a graduate student at UCLA estimates changes in legal cannabis supply pre and post Ogden memo for medical cannabis states (Smart, 2015). Results suggest the Ogden memo had a significant impact on cannabis supply in states with poorly regulated medical cannabis systems.
softening of the first Cole memo and an affirmation that Washington and Colorado would be allowed to experiment with non-medical legalization (Barcott, 2015; Southall & Healy, 2013).

Part II

Medical Cannabis Legislation in Washington

Initiative (I) 692

Ballot measure I-692 calling for legalization of medical cannabis in Washington passed with 59% of the vote in November 1998 (Ballotpedia, 2015). Enacted in December 1998, I-692 provided that individuals may possess up to a 60-day supply of cannabis and identify one primary caregiver to act on their behalf. No provisions for collective gardens or dispensaries were offered in the language of the bill, but rules indicated that authorized patients may cultivate cannabis at home. I-692 afforded an affirmative legal defense for patients with a written recommendation from a doctor and specified qualifying medical conditions for patients as cancer, HIV or AIDS, glaucoma, seizure disorders, and intractable pain. The initial policy did not codify patient protections or formal regulatory structures for growing, processing, distributing, or purchasing cannabis. Given strict federal prohibition of medical cannabis, much of Washington’s medical cannabis activity operated in an undefined, legal grey area (Hunt & Miles, 2015; Parrish, 2010; Wallach, 2014). Lack of clear state-level medical cannabis regulation would mostly persist until 2015.

By 2000, the state legislature had expanded qualifying conditions for medical cannabis to include any disease that resulted in nausea, vomiting, appetite loss, cramping, seizures, muscle spasms, or spasticity (Lemon & Hanley, 2014). In 2002, a Federal Appeals Court ruled that physicians have a first amendment right to discuss medical cannabis treatment without threats from the DEA to revoke medical licenses. By early 2004, the first medical cannabis clinic began writing recommendations for patients in Seattle (Cannabis Defense Coalition, 2012). Although no official records exist as to the number of medical cannabis patients or supply points at this time, reports suggest that Washington’s medical cannabis system remained small in 2004 despite six years in existence (Barcott, 2015). Patient access to cannabis likely consisted of home cultivation or purchasing on the black market.

Senate Bill (SB) 6032

In response to multiple court rulings, the legislature sought to clarify aspects of I-692. In 2007, SB 6032 directed the Department of Health (DOH) to define a 60-day supply of cannabis, loosened the language restrictions on medical recommendations (it was now accepted that patients may benefit from cannabis as opposed to the previous requirement that they would likely benefit), and replaced the term primary caregiver with designated care provider. Designated care providers need not be responsible for the housing, health, or care of the medical cannabis patient and, therefore, could serve solely as cannabis suppliers. This definitional change is likely the primary loophole under which medical cannabis dispensaries began to operate. There was no provision for dispensaries under either I-692 or SB 6032, but enterprising suppliers surmised that if only one patient was served at a time, they may potentially operate in a legal grey area as a rotating designated care provider for each individual patient (Cannabis Defense Coalition, 2012). While it is unclear if this defense would have stood up in court (Stanley,
In 2010, passage of SB 5798 broadened the classification of medical professionals who could provide cannabis recommendations to include naturopathic doctors, physicians’ assistants, and advanced registered nurse practitioners. SB 5073 followed in 2011 as a concerted attempt to regulate grey market cannabis supply with registration, licensing, and regulation provisions for grey market dispensaries (Kleiman, 2015). Collective gardens were expressly permitted and up to 10 patients or care providers could share resources to cultivate medical cannabis for personal use. Despite broad support for the bill from the Seattle city council, the registry, licensing, and regulation provisions were vetoed by Governor Gregoire. The governor stated that such action would make DOH employees, tasked with regulating medical cannabis outlets, vulnerable to prosecution under federal law. Although prosecution of state employees by federal authorities for actions complying with state cannabis laws is feasible under the CSA, the American Civil Liberties Union reports that the federal government had never taken such action regarding cannabis laws (Barcott, 2015; Gutierrez, 2011). Many have attributed the governor’s veto to a letter from U.S. Attorneys Durkan of Seattle and Ormsby of Spokane claiming that, if the governor signed the bill, there would be prosecutions and civil penalties for dispensaries, growers, landlords, and financiers of growers or dispensaries and DOH employees involved in the new regulatory scheme would be subject to the same crackdown (Martin, 2011). Somewhat counterintuitively, SB 5073 established collective gardens as a viable cannabis supply point but, as a result of the partial veto, failed to regulate or license them in any meaningful way, likely creating more confusion for law enforcement. Some prominent advocates of non-medical cannabis legalization supported Governor Gregoire’s veto, foreseeing both the unintended problems and an opportunity to wrap medical cannabis regulation in with a new bill legalizing non-medical cannabis (Barcott, 2015).

Clear regulation of medical cannabis arrived in April 2015, 17 years after medical cannabis legislation first passed. SB 5052 required licensing and regulation of medical cannabis shops under the Liquor Control Board (now named the Liquor and Cannabis Board [LCB]) and created the state’s first system of identifying and tracking medical cannabis patients. All dispensaries were phased out and replaced by I-502 shops with medical designations conferred by the state. Collective gardens continued as an access point but were renamed cooperatives, required to register with the state, and were reduced in size to 4 qualifying patients. SB 5052 also offered the first protection from arrest for medical cannabis patients and providers with recognition cards and increased possession limits for patients who voluntarily registered with the state. Governor Inslee vetoed portions of the law that would have created new felonies for selling medical cannabis outside the state regulatory structure (Capecchi, 2015).
Non-Medical Cannabis Legislation in Washington

I-75

Early medical cannabis policies occurred in tandem with a softening of criminal justice enforcement regarding non-medical cannabis. In 2003, Washington’s largest city, Seattle, passed I-75 declaring cannabis the lowest priority for the city’s law enforcement (Boruchowitz, 2010). In 2007, an 11 member panel appointed by the city council president completed an evaluation of I-75, using data from official case referrals from the Seattle Police Department and a tracking system for cannabis cases created by the City Attorney’s office for 2000-2006. The panel was unable to definitively attribute any observed trends directly to I-75 and voted 9-2 that there were no apparent reasons to repeal the city ordinance. Their position cited lack of evidence of increases in adolescent cannabis use, crime, or other public health issues. They also noted reductions in cannabis-related criminal justice contact for adults and savings on public safety resources after implementation of I-75 (Boruchowitz, 2010; Marijuana Policy Review Panel, 2007). In 2011, Washington’s third most populous city, Tacoma, followed Seattle’s lead with I-1 declaring cannabis the lowest law enforcement priority in the city. A comparable measure failed in Spokane, the second largest city in Washington (Ballotpedia, 2015).

I-502

In November 2012, voters passed I-502 with 56% in favor making Washington one of two states to legalize non-medical cannabis that year. Backers of I-502 aimed to bring black market cannabis under state control, increase tax revenue, and legitimize non-medical marijuana use that was already widespread. Others hoped for a reduction in cannabis-related policing, judicial, and social costs that have been a disproportionate burden on people of color (ACLU, 2015; Beckett & Herbert, 2008). Reports indicated that despite lower levels of cannabis use, African Americans in Washington were 2.9 times more likely than Whites to be arrested for cannabis possession between 2001 and 2010. Native Americans and Latinos faced a similar situation, being 1.6 times more likely to be arrested than Whites (Levine, Gettman, & Siegel, 2012). In contrast to collective gardens and dispensaries previously providing medical cannabis, retail access points for non-medical cannabis, typically referred to as I-502 shops, were closely taxed, tracked, licensed, and regulated by the LCB. I-502 set the legal age for purchase and possession at 21 and the maximum possession amount at 16 ounces of usable cannabis or 72 ounces of cannabis-infused liquid. The law explicitly outlawed home cultivation of cannabis (ACLU, 2015; Barcott, 2015). I-502 took effect in December 2012, but the first I-502 shop did not open until July 2014 and with a second following in October 2014. Due to licensing and regulatory requirements, I-502 shops opened slowly over time and policy implementation lagged (ACLU, 2015). Between March and December 2014, 326 non-medical cannabis licenses were issued to producers, 287 to processors, and 97 to retailers (Hitchcock, Laurent, & McGroder, 2015). Ultimately, 334 retailer licenses were slated to be issued in Washington (Washington State Liquor and Cannabis Board, 2015).
House Bill (HB) 2136

Non-medical cannabis legislation was revised with HB 2136 in July 2015. Under I-502, a 25% excise tax had been assessed at three points: grower to processor, processor to retailer, and retailer to customer (all of which were required to be separate business entities). HB 2136 instituted a single 37% tax levied at the point of purchase, lowering taxes overall. HB 2136 also confirmed the power of cities and counties to pass local bans or moratoria against cannabis sales within their borders. Although Washington’s alcohol laws allow for dry counties, no such provision was provided in I-502, leading to disagreement between cities and business operators. Local governments that allow I-502 shops share in tax revenues from cannabis sales, while those instituting bans do not (Bricken, 2015; McVay, 2015). According to the director of the LCB, the tax changes in HB 2136 will likely drive down prices for medical and non-medical cannabis (Garza, 2015).

Conclusions and Recommendations

The previous pages describe Washington’s complex history of cannabis legislation. Much is still unknown about the impact of these policy changes. For all states, we need policy evaluations that are flexible, nuanced, contextualized, and sensitive to the complexity of evolving state-level cannabis policies. We offer four recommendations for future cannabis policy evaluations and highlight their relevance using examples from Washington’s history. First, Washington has enacted numerous policies that may potentially influence cannabis supply or demand and, in turn, consumption. Yet, evaluations typically focus only on medical (1998) or non-medical legislation (2012). Cannabis policy studies should consider all important policy changes and implementation dates of key policy components. Evaluations should specify the hypothesized pathways through which each policy component may impact cannabis use.

Second, medical cannabis dispensaries have a long history in Washington despite no official provision in state law. Despite their prohibition in state law, more than 300 dispensaries in Washington in 2015 were voluntarily identifying themselves through online advertising (Leafly.com, 2015; Weedmaps.com, 2015)4 or taxes paid to the state (S. Smith, personal communication, March 5, 2015). It is essential that evaluations consider the on-the-ground realities for all factors potentially impacting cannabis supply or demand and not just those factors provided for in state laws.

Third, state-level policies and action by the federal government may interact to influence cannabis supply within a state. Unclear regulation of dispensaries in Washington likely allowed the green rush to take hold within the state after the arrival of the Ogden memo. While specific changes to the medical cannabis market post-Ogden memo are difficult to estimate given lack of dispensary or medical cannabis patient tracking (Fairman, 2015), Washington media reports suggest that approximately 130 new dispensaries opened from late 2009 through early 2011 (Martin, 2011). This indicates a substantial expansion of the grey market and mirrors changes in other green rush states at this time (Schuermeyer et al., 2014). Advertising data, business licensing records for dispensaries or

4 Advertising data was gathered by the first author using the search terms “dispensary” and “Washington” on both sites and removing duplicates.
tax records, and estimates of medical cannabis patient counts may potentially yield approximate measures of the size of cannabis markets in Washington or other states without explicit dispensary tracking. Our analysis of Washington’s policy history illuminates the policy path through which post-Ogden memo increases in supply occurred and offers support for suggestions by other scholars that 2009 represents one point in time whereby evaluators should investigate changes in cannabis use (Sznitman & Zolotov, 2015; Wang et al., 2013). It remains an open question if this policy interaction directly or indirectly impacted cannabis norms. Comprehensive cannabis policy evaluations should consider changing federal polices as well as potential interactions between state and federal policies.

Finally, it is essential that future cannabis policy evaluations consider the historical legacies of established cannabis policy regimes when evaluating current and future policy initiatives. For example, local reports suggest that the initial impact of non-medical cannabis legalization in 2012 was conditioned by the poorly-regulated market for medical cannabis in Washington. Policy tracking by health officials in King County, which includes Seattle and surrounding cities, have described how cities and counties employed moratoria and zoning regulations to limit the activities of cannabis suppliers after the passage of I-502 (Hitchcock et al., 2015). From 2013 to 2014, 70 local jurisdictions installed bans or moratoria on recreational cannabis stores and 53 jurisdictions enacted new bans or moratoria on medical cannabis collective gardens. By 2015, half of 180 larger local jurisdictions had employed zoning regulations to enact local controls on cannabis suppliers. Washington officials attributed the increase in collective garden bans and low medical cannabis zoning rates as a community response to “the apparent proliferation of unregulated dispensaries, as more businesses apparently enter the market place” (Hitchcock et al., 2015). These reports suggest that I-502 had the unintended consequence of expanding grey market cannabis supply. It is unknown what impact I-502 may have had on cannabis norms. To support these recommendations and provide more nuanced evaluations of changing cannabis policies, it is essential that states and communities carefully track the implementation of policy components in the wake of new cannabis policies as well as both intended and unintended consequences of policy change.


Smith, S. (2015, March 5). [Medical marijuana tax rate].


